Bio-Techne Releases 32×8 Cartridge For The Ella Platform

MINNEAPOLIS, July 17, 2019 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of a new 8-Plex cartridge format for the ProteinSimple™-branded Ella™ automated immunoassay platform. This new cartridge format analyzes 32 samples for eight distinct analytes, bringing higher multiplex capabilities to the Ella platform.

The 32×8 cartridge for Ella enables users to build panels of up to eight analytes, which are selected from a pool of pre-validated analytes that are putative biomarkers for a variety of diseases, including inflammation and cancer. These multiplex assays are validated to the same high standards of a single plex assay, allowing users to seamlessly transition between plex levels and cartridge formats.

Dave Eansor, President of Bio-Techne’s Protein Sciences Segment, commented, “The 32×8 cartridge expands the impressive performance of the Ella platform to a critical plex level. The ability to monitor eight analytes with extremely high sensitivity and precision in just 25 ml volume of a precious biological sample is a notable breakthrough for clinical biomarker research.”

The Ella platform allows users to perform high-quality immunoassays in 90 minutes with no manual intervention. This innovative immunoassay workflow decreases the iteration time of research and empowers staff to spend their time on higher value activities. Other Simple Plex cartridge formats currently offered include multianalyte formats that measure either 16 or 32 samples for up to four biomarkers, a single plex cartridge format, and a customizable cartridge that accommodates user defined reagents.

About Bio-Techne Corporation (NASDAQ: TECH)

Contact: David Clair, Investor Relations
ir@bio-techne.com
646-277-1266

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-releases-32×8-cartridge-for-the-ella-platform-300886073.html

SOURCE Bio-Techne Corporation

Staff

Recent Posts

Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia

LUND, SWEDEN / ACCESSWIRE / March 27, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq…

1 hour ago

RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting

Relief Therapeutics Calls Extraordinary General Meeting Anticipated Board of Directors OverhaulGENEVA, SWITZERLAND / ACCESSWIRE /…

1 hour ago

PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease

Pivotal Trial for Improving Overall Function and Quality of LifeSALT LAKE CITY--(BUSINESS WIRE)--#medicaldevices--PhotoPharmics, a pioneer…

10 hours ago

AARC Celebrates Introduction of the SOAR Act in the House of Representatives

Bill passage key to supplemental oxygen access and adequate reimbursementIRVING, TX / ACCESSWIRE / March…

13 hours ago

She Is Not Skipping a Beat, and Patients Are Noticing

NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Quest Diagnostics At Quest for 2…

13 hours ago